\Box

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasi ii iytori,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL		
OMB Number:	MB Number: 3235-0287	
Estimated average bu	urden	
hours per response:	0.5	

	Check this box if no longer subject to
١	Section 16. Form 4 or Form 5
ı	obligations may continue. See
	Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer Name and Address of Reporting Person* (Check all applicable) Applied Therapeutics Inc. [APLT] Silberstein Charles Director 10% Owner Officer (give title Other (specify X below) below) 3. Date of Earliest Transaction (Month/Day/Year) (Last) (First) (Middle) 12/14/2021 Chief Financial Officer C/O APPLIED THERAPEUTICS, INC. 545 FIFTH AVENUE, SUITE 1400 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable (Street) Form filed by One Reporting Person **NEW YORK** 10017 NY Form filed by More than One Reporting (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 5. Amount of 6. Ownership 7. Nature of Indirect Beneficial Transaction Securities Beneficially (Month/Day/Year) (D) or Indirect if any (Month/Day/Year) Code (Instr. 5) 8) Owned Following (I) (Instr. 4) Ownership Reported (Instr. 4) Transaction(s) (Instr. 3 and 4) (A) or (D) ν Price Code Amount 47,900(1) Common Stock 12/14/2021 A \$0.00 135,703 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 6. Date Exercisable and 7. Title and Amount of Securities Underlying Derivative Security 1. Title of 3. Transaction 3A. Deemed 5. Number 8. Price of 9. Number of 11. Nature Date (Month/Day/Year) Execution Date, Expiration Date (Month/Day/Year) derivative Securities of Indirect Beneficial Conversion Transaction Ownership Derivative Security (Instr. 3) or Exercise if any Code (Instr. Security (Instr. 5) Form: (Month/Day/Year) Direct (D) Price of 8) Securities Beneficially Ownership Acquired (A) or Disposed Derivative Security (Instr. 3 and 4) Owned Following or Indirect (I) (Instr. 4) (Instr. 4) Reported of (D) (Instr 3, 4 and 5) Transaction(s) (Instr. 4)

Explanation of Responses:

\$9,44

1. Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the compensatory Restricted Stock Units shall vest on each of December 14, 2022, December 14, 2023, December 14, 2024 and December 14, 2025, subject to the Reporting Person continuing to provide services through each such date.

Date

Exercisable

(2)

(D)

(A)

32,000

Code

A

Expiration

12/14/2031

Title

Stock

2. Consists of compensatory options granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. One-fourth (1/4th) of the shares subject to the compensatory Option shall vest on December 14, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

Remarks:

Employee Stock

(Right to Buy)

Option

/s/ Shoshana Shendelman as attorney-in-fact

Amount or Number

Shares

32,000

\$0.00

12/16/2021

32,000

D

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

12/14/2021

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.